Recent efforts by leading AI developers are markedly advancing biological and pharmaceutical research. DeepMind unveiled AlphaGenome, an AI model predicting gene regulation effects from DNA sequence variations, aiming to streamline genetic variant interpretation. Gero introduced ProtoBind-Diff, a diffusion language model generating drug-like molecules conditioned only on protein sequences, bypassing the need for structural data. Additionally, SandboxAQ released SAIR, a large public dataset of protein-ligand structures with binding affinities to empower AI-driven drug discovery. These strides underscore AI's growing ability to accelerate understanding of gene function and to design novel therapeutics with increased precision and efficiency.